Diepenbeek

Researchers are evaluating a medicine called MK-1045 in adults aged 18 to 75 who have systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). The study aims to learn about the safety of MK-1045 and how well people tolerate it at different doses. Participants with SLE must have had their diagnosis for at least 6 months and meet specific classification criteria while taking at least one background therapy. Those with RA must also have had their diagnosis for at least 6 months and meet established classification criteria. The study involves giving MK-1045 through an intravenous infusion. This is a Phase 1 dose escalation study, meaning participants receive increasing doses of the medicine to assess safety and how the body processes it. The study monitors participants over multiple parts; the first part observes adverse events up to about 12 weeks, and subsequent parts continue monitoring for up to approximately 52 weeks. Participants may discontinue the study drug if they experience adverse events. During the study, researchers will track adverse events and reasons for stopping the medicine, collect information on how the medicine behaves in the body, and monitor participants’ health throughout. Safety and tolerability are the main outcomes, and the study includes ongoing evaluations for up to a year after starting treatment. Participants will have regular check-ins to assess their condition and any side effects while using MK-1045.

This research aims to evaluate the effects of a flavonoid-rich Mediterranean diet on people with multiple sclerosis (MS), a condition influenced by various factors including nutrition. The study focuses on whether adopting this healthier dietary pattern can impact disease-related measures. Participants will follow a specialized Mediterranean diet adjusted to emphasize foods high in flavonoids. This diet is guided by specific dietary recommendations designed to increase the intake of these beneficial compounds. Throughout the study, researchers will monitor changes in the participants' microbiota at three timepoints: before starting the strict diet (day 14), after completing the diet (day 31), and following a three-month follow-up period (day 122). These measures will help assess the diet's impact on the participants over time.

Researchers are evaluating the effectiveness and safety of brenipatide compared to a placebo in adults with Alcohol Use Disorder (AUD) and hazardous alcohol use. This Phase 3, multicenter, randomized, double-blind study aims to understand if brenipatide can help participants reduce or stop drinking. The study lasts approximately 56 weeks and focuses on changes in drinking patterns using the Timeline Followback Method (TLFB). Participants will receive either brenipatide (LY3537031) or a placebo, both administered by subcutaneous injection. Participants who cannot self-inject will have assistance from a trained support person. They are expected to store and use the blinded study drug as directed, maintain electronic and paper diaries, and complete questionnaires throughout the study. During the study, participants will have scheduled visits to monitor their progress, including assessments of drinking behavior and safety evaluations. Researchers will measure changes in alcohol use patterns up to 56 weeks. Participants must be motivated to reduce or stop drinking and be available for all study visits and procedures. Safety and adherence will be closely monitored throughout the trial.

Researchers are evaluating the safety and effectiveness of brenipatide compared to a placebo for adults with moderate-to-severe Alcohol Use Disorder (AUD). This phase 3 study aims to better understand if brenipatide can help reduce drinking in this population. Participants will be followed for about 56 weeks to gather comprehensive information. Participants will receive either brenipatide (LY3537031) or a placebo, both given by subcutaneous injection. The study involves a randomized, double-blind design, meaning neither the participants nor the researchers know who receives which treatment during the trial. This method helps provide reliable results about the effects and safety of brenipatide. During the study, participants will attend scheduled visits, self-inject the study drug, and complete electronic and paper diaries as well as questionnaires. Researchers will monitor changes in drinking patterns using the Timeline Followback Method for up to 56 weeks. Safety monitoring and regular assessments will be performed throughout the study to track participants' health and adherence.

Researchers are evaluating the safety and effectiveness of eloralintide, a drug given by injection, in adults who are obese or overweight but do not have type 2 diabetes. This Phase 3 study includes both a main phase and an extension phase to understand the drug's impact on body weight and overall health in this population. The study aims to compare eloralintide with a placebo to see how well it works in reducing weight. Participants will receive either eloralintide or a placebo, both administered under the skin once a week. The main study phase will last about 75 weeks, during which participants will be regularly monitored. Those participants who have prediabetes will have the option to continue into an extension phase lasting an additional 2 years to further assess long-term effects. During the study, participants will have their body weight measured at the start and throughout the trial, with the primary outcome being the percent change in body weight at week 64 compared to baseline. Researchers will also monitor safety and any side effects. Participants will be asked about their weight history and health conditions, and they must maintain stable body weight before joining. The total involvement time for most participants will be about 75 weeks, with longer follow-up for some.

Researchers are investigating how people with multiple sclerosis (MS) perceive their motor performance compared to healthy individuals. The study focuses on understanding perceptive abilities during prolonged functional tasks like walking and repeatedly standing up from a seated position. By comparing self-reported perceptions and actual performance, the study aims to identify specific deficits in people with MS that could help tailor additional interventions beyond standard care. Participants will complete two main experimental tasks over a maximum of three days. The first task involves walking at maximum speed for six minutes and reporting perceived changes in speed or smoothness using a handheld haptic device. The second task requires repeated sit-to-stand transitions at a fixed pace, again reporting perception changes. A second work package includes treadmill walking with imposed speed changes and sit-to-stand transitions with adjustable chair heights to assess perceptive accuracy for externally imposed variations. Wearable sensors will objectively record motor performance during all tasks. During the study, participants will provide demographic information and complete questionnaires on physical activity, sleep, self-efficacy, mood, symptoms, fatigue, and body perception. Motor and cognitive tests will be performed, including walking speed, balance, memory, and proprioception assessments. Fatigue levels will be measured before and after tasks. Researchers will compare reported perceptions with actual performance to assess sensitivity, detection accuracy, and correspondence accuracy in motor tasks.

This research aims to understand how different levels of fatigue during power training affect strength, movement, and muscle function in healthy older adults aged 65 to 85 years. The study focuses on how fatigue impacts recovery, muscle soreness, and the perceived difficulty of exercise. Researchers want to find out which approach to power training might be safest and most effective for this population. Participants will take part in three supervised power-training sessions on a pneumatic leg press machine, each about one week apart. The sessions vary by fatigue level: one stops when movement speed drops by 10%, another stops at a 30% speed drop, and the third matches the total work of the 30% session but stops at 10% velocity loss. Each session consists of four sets of training. During the study, participants will perform exercises and undergo strength and mobility tests before and after each session. Small blood samples will be collected to observe body responses, and participants will rate how hard the exercise feels and report muscle soreness for up to two days after. Researchers will measure muscle strength through maximum voluntary contraction before, 5 minutes after, and 24 hours after exercise to assess recovery and function.

Researchers are evaluating the safety and effectiveness of a medicine called NNC0487-0111 for adults with excess body weight, specifically targeting obesity. This Phase 3 clinical study aims to see if this treatment helps people maintain their weight loss compared to a placebo, which contains no active medicine. Participants are randomly assigned to either the treatment or placebo group to fairly compare results. The study involves two groups receiving weekly injections under the skin: one group gets NNC0487-0111, and the other receives a placebo designed to look the same. The treatment is given once a week, and participants reach a target dose during an initial run-in period before the main study phase begins. During the study, researchers track changes in body weight from week 40 to week 92 to assess how well the treatment works. Participants' safety and health are monitored throughout the study, including various medical assessments. The total participation time covers these weeks and includes ongoing observation to understand the treatment's effects over time.

Multiple sclerosis (MS) is a chronic disease affecting the central nervous system, often causing walking difficulties, balance problems, fatigue, cognitive challenges, and higher fall risks. These issues can appear early in the disease and may not be fully detected by standard walking tests that mainly measure speed or distance. Walking adaptability, which involves adjusting gait to obstacles and unexpected changes, is crucial for safe movement and preventing falls but is not well understood in people with MS. The study involves 16 people with MS and 16 healthy adults matched by age and sex. It includes a single testing session where participants perform various walking and motor tests using movement sensors and self-report questionnaires to assess balance, fatigue, walking ability, and cognitive function. Proactive gait adaptability is tested by walking on a 10-meter path with stepping targets under different conditions, while reactive gait adaptability is measured using an advanced augmented reality system that applies unexpected perturbations during treadmill walking. Brain activity related to walking is recorded using a special cap during both tests. Participants will complete several motor performance tests like the Timed 25-Foot Walk and 6-Minute Walk, as well as questionnaires about falls, walking confidence, fatigue, and cognition. Researchers will measure how well participants adapt their walking patterns and brain responses. The primary outcomes include performance on the Walking Adaptability Ladder Test, reactive gait adjustments, and changes in brain oxygen levels. This helps understand walking adaptability in MS and may guide future rehabilitation strategies.

This research aims to promote healthy and sustainable eating habits and prevent weight gain among Flemish higher education students during their transition from secondary school to higher education. The project evaluates two multi-component dietary interventions over eight weeks at a university and a college. These interventions focus on encouraging healthier lifestyle choices during a period when unhealthy eating and weight gain are common, and they are part of a broader strategy to reduce cancer risk factors. The interventions include behavioral nudges in student cafeterias, social media campaigns on Instagram, and interactive workshops designed to support healthy eating. The campus environment will be adjusted with subtle changes such as redesigning dining areas and highlighting healthier food options to influence students' choices without restricting their freedom. Information stands on campus will also provide opportunities for students to learn, ask questions, and try sustainable and healthy products. Sales data from student restaurants will be collected from February to May 2025 to assess changes in purchasing behavior. Participants will complete questionnaires at three points: before the intervention, immediately after, and five months later to measure nutrition behavior, attitudes, knowledge, self-efficacy, perceived food environment, intentions, barriers, cooking skills, weight, and height. A process evaluation will involve focus groups with students and stakeholders and process questionnaires to understand the intervention's implementation and participant experiences. Two other campuses will act as control groups for comparison. If effective, the program may be expanded to other Flemish institutions.